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Objectives This study sought to demonstrate the noninferiority of polymer-free amphilimus-eluting stents (Cre8, CID, Salug-
gia, Italy) versus permanent-polymer paclitaxel-eluting stents (Taxus Liberté, Boston Scientific, Natick, Massachu-
setts) in de novo percutaneous coronary intervention.
Background Although the efficacy of the drug-eluting stent has been well established, the risk-benefit balance is still subopti-
mal, and the safety of polymers remains uncertain.
Methods Patients undergoing percutaneous coronary intervention for de novo lesions were randomly assigned 1:1 to Cre8
or Taxus Liberté stents. Primary endpoint was 6-month angiographic in-stent late lumen loss (LLL) within a non-
inferiority scope. Six-month intravascular ultrasound was performed in 20% of the patients. All patients will be
clinically followed up to 5 years.
Results Out of 323 patients enrolled, 162 received Cre8 and 161 Taxus Liberté stents. In-stent LLL was significantly
lower in Cre8 group (0.14  0.36 mm vs. 0.34  0.40 mm, p noninferiority 0.0001, p superiority 0.0001).
Clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis) up
to 12 months did not differ significantly between the groups.
Conclusions The Cre8 stent in de novo lesions showed significantly lower in-stent LLL at 6 months than the Taxus Liberté
stent did, with a trend toward better 12-month clinical safety and efficacy results. (International Randomized
Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo
Coronary Lesions [NEXT]; NCT01373502) (J Am Coll Cardiol 2012;59:1371–6) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.009Drug-eluting stents (DES) represent a breakthrough tech-
ology that has profoundly affected the treatment of
oronary artery disease (1,2). Most DES are composed of
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2011, accepted December 6, 2011.metallic stent platform, antiproliferative drug agent, and
its carrier, most frequently a polymer, which modulates
drug diffusion into the vessel wall and release kinetics.
Although mid-term DES efficacy has been well estab-
lished, there is an increased incidence of late stent
thrombosis (3,4), particularly after discontinuation of
thienopyridine therapy.
A strategy to limit the potential negative influence of this
serious event was the introduction of biodegradable poly-
mers (5,6). Nevertheless, several in vivo investigations still
reported an extensive inflammatory response (7–9).
Therefore, the best strategy to overcome these drawbacks
is a polymer-free (PF) metallic DES (10,11) or a bioresorb-
able DES (12).
The Cre8 stent (CID, Saluggia, Italy) PF DES was
studied, in a prospective single-blinded randomized mul-
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Randomized Trial of Amphilimus Versus Paclitaxel Stents April 10, 2012:1371–6ticenter trial, for noninferiority
in terms of 6-month angio-
graphic in-stent LLL compared
to permanent-polymer (PP)
Taxus Liberté (Boston Scien-
tific, Natick, Massachusetts).
Methods
Studydesign andpatient selection.
Patients from 11 centers were
randomly assigned in a single-
blinded fashion to receive either
Cre8 or Taxus Liberté (Taxus).
Patients were eligible if they had
stable or unstable angina or silent
ischemia with single de novo le-
sions 20 mm length, at a maximum 2 different coronary
rteries with a diameter ranging from 3.0 to 3.75 mm.
ajor exclusion criteria were percutaneous coronary in-
ervention within 30 days, acute myocardial infarction
ithin 72 h, renal failure, left ventricular ejection fraction
30%, or other significant comorbidities.
Angiographic exclusion criteria were left main disease,
ifurcation and ostial lesions, chronic total occlusions,
resence of severe calcification, or excessive tortuosity. The
tudy was approved by each participating institution’s ethics
ommittees, conducted according to good clinical practice
nd Helsinki’s Declaration. All patients provided written
nformed consent.
tudy device. The Cre8 stent is a polymer-free stent with
thin (80-m) cobalt-chromium alloy L605, integrally
coated by an ultra-thin (0.3-m) passive carbon coating
i-Carbofilm, CID, Saluggia, Italy). The amphilimus for-
ulation, constituted by sirolimus (0.9 g/mm2) formu-
ated with an excipient composed of long-chain fatty acids
ixture, to modulate the drug release, is loaded into
bluminal reservoirs to obtain a targeted elution toward the
essel wall.
andomization and masking. A computer-generated
locked randomization list was used to allocate patients on
1:1 basis to one of the study arms and to the intravascular
ltrasound (IVUS) substudy. Allocation was insured by
equentially numbered and sealed envelopes. Patients,
embers of the clinical event committee, and angiographic
nd IVUS core laboratory personnel were masked to treat-
ent allocation.
tudy procedures. Randomized patients received a Cre8 or
Taxus stent after the lesion was crossed by the guidewire.
ixty patients, 30 in each arm, were also selected for IVUS
ubstudy, at 3 pre-selected sites.
Pre-dilation was mandatory. Available stent sizes were
.0 and 3.5 mm, whereas stent lengths ranged from 12 to
5 mm.
Periprocedural anticoagulation with heparin or bivaliru-
Abbreviations
and Acronyms
CK  creatine kinase
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
LLL  late lumen loss
MI  myocardial infarction
PF  polymer-free
PP  permanent polymer
QCA  quantitative
coronary angiography
TLR  target lesion
revascularizationin and administration of glycoprotein IIb/IIIa inhibitorsas according to local practice. Post-procedure dual-
ntiplatelet therapy was mandated for at least 6 months,
ith indefinite continuation of aspirin. Electrocardiograms
ere recorded at baseline and within 24 h after the proce-
ure. Creatine kinase (CK) and CK-myocardial band frac-
ion were measured at baseline and within 12 to 24 h after
tenting. All patients underwent angiographic follow-up at
months and clinical follow-up at 30 days, 6 months, and
nnually thereafter for 5 years.
ata management, endpoints, and definitions. Collected
ata were monitored, with 100% verification against source
ata, and entered into an electronic database (Oracle Clin-
cal, Redwood Shores, California).
Clinical events (death, myocardial infarction, stent
hrombosis, revascularization procedures, and cerebrovascu-
ar events) were adjudicated by an independent clinical event
ommittee.
Primary endpoint was 6-month angiographic in-stent
LL measured by quantitative coronary angiography
QCA). Secondary clinical endpoints included death, myo-
ardial infarction (MI) (according to the World Health
rganization definition based on CK and CK-myocardial
and rise) (13). Target lesion revascularization (TLR) (de-
ned as repeat PCI or coronary artery bypass graft of the
arget lesion), target vessel revascularization (defined as
epeat PCI or coronary artery bypass graft of the target
essel) and composite endpoints of major adverse cardiac
vents (death, MI, and TLR), target vessel failure (cardiac
eath, target vessel-related MI, clinically driven TLR, or
arget vessel revascularization), TLF (cardiac death, target
Figure 1 Trial Profile Showing the
Number of Randomized Patients
IVUS  intravascular ultrasound; QCA  quantitative coronary angiography.
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bosis were adjudicated according to the Academic Research
Consortium classification (14). Secondary endpoints also
included device success (attainment of 30% in-stent re-
sidual stenosis of the target lesion, by QCA, using the
assigned device) and procedure success (attainment of a final
lesion success and no in-hospital major adverse cardiac
events up to 7 days after the index procedure).
Quantitative coronary angiography. All angiograms ac-
quired using standardized instructions were analyzed by an
independent core laboratory (Bioclinica, Leiden, the Neth-
erlands). The QCA was performed using standard image
quantification software (Medis, Leiden, the Netherlands).
LLL was defined as the difference between minimal lumen
diameter immediately after the procedure and 6-month
minimal lumen diameter (MLD), diameter stenosis was
calculated as: [1  (MLD/RVD)]  100 (RVD is the
reference vessel diameter). Binary restenosis was defined as
a reduction of 50% or more of the luminal diameter in the
target lesion. Measurements were obtained within the stent
(in-stent) and within the segment (in-segment, including
the stented segment and 5 mm proximal and distal to the
stent).
Intravascular ultrasound. Serial IVUS imaging was per-
formed after stent implantation and at 6-month follow-up.
Quantitative IVUS measurements were performed by inde-
Clinical and Lesion CharacteristicsTable 1 Clinical and Lesion Characteristics
Cre8*
(n  162)
Taxus Liberté*
(n  161)
Demographics
Age, yrs 64.90 10.20 64.39 10.45
Male 124/162 (76.5) 109/161 (67.7)
Risk factors
Current smoking 39/162 (24.1) 40/161 (24.8)
Dyslipidemia 102/162 (63) 98/161 (60.9)
Diabetes
ID diabetes 10/162 (6.2) 11/161 (6.8)
Non-ID diabetes 38/162 (23.5) 28/161 (17.4)
Hypertension 104/162 (64.2) 104/161 (64.6)
History
Prior myocardial infarction 14/162 (8.6) 15/161 (9.3)
Prior PCI 26/162 (16.0) 23/161 (14.3)
Targeted coronary artery
LAD 86/188 (45.7) 90/189 (47.6)
LCX 48/188 (25.5) 39/189 (20.6)
RCA 54/188 (28.7) 60/189 (31.7)
Lesion type, ACC/AHA
A 37/188 (19.7) 36/189 (19.0)
B1 102/188 (54.3) 101/189 (53.4)
B2 35/188 (18.6) 45/189 (23.8)
C 14/188 (7.4) 7/189 (3.7)
Moderate or severe calcification 44/188 (23.4) 35/185 (18.5)
Lesion length, mm 15.41 6.99 15.15 7.08
Values are mean  SD or n/N (%). *For all comparisons, p  NS.
ACC/AHA  American College of Cardiology/American Heart Association; ID  insulin-a
dependent; LAD left anterior descending artery; LCX left circumflex artery; PCI percutaneous
coronary intervention; RCA  right coronary artery.pendent core laboratory (Bioclinica) using dedicated soft-
ware (Medis).
Statistical analysis. The study sample size was determined
based on the primary endpoint of 6-month in-stent LLL,
assuming no difference in mean, a noninferiority delta of
0.16 mm, and a standard deviation of 0.50 mm.
Given these assumptions, 250 subjects would have pro-
vided an 80% power to demonstrate the noninferiority
between the 2 groups. To account for dropout and to ensure
enough angiographic data, approximately 300 patients were
required. For continuous variables, differences between
groups were evaluated by Student t test, whereas for discrete
ariables chi-square or Fisher exact tests were used. Nor-
ality of angiographic endpoints’ distribution was verified
nd Wilcoxon-Mann-Whitney test was adopted instead of
tudent t test when appropriate.
The p value for noninferiority was 1-tailed, and all
ther p values were 2-tailed. Statistical significance was
et at the 0.05 level for superiority and 0.025 for
oninferiority.
Kaplan-Meier cumulative incidence estimates were used
o analyze outcome events, which were compared between
roups using the log-rank test.
Statistical analysis, performed by CID company and
ndependently reviewed by the study coordinating inves-
igator, was conducted according to implanted study
evices. In total, 8 patients were excluded: 7 received
Quantitative Coronary AngiographyTable 2 Quantitative Coronary Angiography
Cre8 Taxus Liberté p Value
Before procedure (n 181 lesions) (n 184 lesions)
RVD, mm 2.76 0.42 2.79 0.43 0.5051
MLD, mm 0.98 0.36 1.00 0.38 0.5475
DS, % 64.26 11.35 64.11 11.56 0.8996
After procedure
RVD, mm 2.92 0.40 2.91 0.44 0.8481
In-stent MLD, mm 2.62 0.37 2.64 0.39 0.7488
In-segment MLD,* mm 2.35 0.43 2.35 0.47 0.9943
In-stent DS, % 9.99 7.33 9.03 8.04 0.2373
In-segment DS,* % 17.56 8.64 18.10 8.47 0.5549
6-month follow-up (n 160 lesions) (n 156 lesions)
RVD, mm 2.86 0.36 2.84 0.42 0.5727
In-stent MLD, mm 2.50 0.47 2.31 0.48 0.0006
In-segment MLD,* mm 2.25 0.47 2.14 0.48 0.0353
In-stent DS, % 12.58 12.23 18.66 11.45 0.0001
In-segment DS,* % 20.53 11.75 24.72 11.95 0.0022
Late lumen loss
In-stent, mm 0.14 0.36 0.34 0.40 0.0001†
In-segment,* mm 0.11 0.36 0.23 0.36 0.0041
Binary restenosis
In-stent 5 (3.1) 3 (2.0) 0.7239
In-segment* 5 (3.2) 6 (4.0) 0.7664
Values are mean  SD or n (%). *In-segment includes the 5-mm segments proximal and distal to
he stent edges; late lumen loss indicates difference between MLD at 6 months and MLD after the
rocedure; and DS 50% at follow-up. †The p value indicates both noninferiority and superiority.
DS  diameter stenosis; MLD  minimal lumen diameter; RVD  reference vessel diameter.dditional nonstudy stents in the target lesion (3 patients
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from the study.
Results
From October 2009 to September 2010, 323 patients were
enrolled: 162 were assigned to Cre8 and 161 to Taxus
groups (Fig. 1). In addition, 48 patients (27 treated with
Cre8 and 21 treated with Taxus) were included in the IVUS
substudy. Baseline clinical presentation and lesion charac-
teristics were similar between groups (Table 1).
Quantitative coronary angiography. Pre- and post-
procedure QCA measurements were performed on 315
patients with 365 lesions (181 Cre8, 184 Taxus).
Six-month angiographic parameters (Table 2) were analyzable
for 276 subjects with 316 lesions (160 Cre8, 156 Taxus). All
angiographic endpoints except minimal lumen diameter were
nonnormally distributed, irrespective of implanted device.
In-stent LLL primary endpoint was lower for Cre8 than
for Taxus (0.14  0.36 mm vs. 0.34  0.40 mm), reaching
statistical significance both for noninferiority (p  0.0001)
Figure 2 6-Month Angiographic Follow-Up
(A) Distribution of 6-month diameter stenosis (with lines showing mean val-
ues). (B) Cumulative frequency of late lumen loss.nd for superiority (p  0.0001). In-stent 6-month diam-
ter stenosis was also significantly lower for Cre8 (12.6 
2.2% vs. 18.7 11.4%, p 0.0001) (Fig. 2A). Cumulative
in-stent LLL frequency showed a median value of 0.07 mm
for Cre8 versus 0.27 mm for Taxus (Fig. 2B). Significant
differences in favor of the Cre8 group were also shown for
other QCA parameters, whereas no difference was found for
in-stent binary restenosis (3.1% vs. 2.0%) (Table 2).
Post hoc subgroup analysis focusing on 82 diabetic
patients (44 lesions Cre8 and 39 Taxus Liberté) confirmed
the significantly lower LLL associated with Cre8 (0.12 
.28 mm vs. 0.43  0.41 mm, p  0.0001).
ntravascular ultrasound. Six-month IVUS analysis was
vailable in 48 patients (27 Cre8, 21 Taxus). The Cre8 stent
roved superior for the pre-specified IVUS endpoints of
eointimal hyperplasia volume (11.8  8.2 mm3 vs. 18.7 
0.1 mm3, p  0.009) and volume obstruction (6.7  2.4%
vs. 11.3  5.6%, p  0.001).
Clinical outcomes. Cumulative 12-month clinical out-
comes showed no significant differences between study arms
Clinical Outcomes at 12 MonthsTable 3 Clinical Outcomes at 12 Months
Cre8
(n  148)
Taxus Liberté
(n  148) p Value
Death, all 2/148 (1.4) 3/148 (2.0) 1.0000
Cardiac 2/148 (1.4) 1/148 (0.7) 1.0000
Noncardiac 0/148 (0) 2/148 (1.4) 0.4983
MI, all 1/148 (0.7) 2/148 (1.4) 1.0000
Q-wave 1/148 (0.7) 2/148 (1.4) 1.0000
Non–Q-wave 0/148 (0) 0/148 (0) —
Repeat revascularization, all 13/148 (8.8) 12/148 (8.1) 0.8344
TLR 7/148 (4.7) 9/148 (6.1) 0.6072
Clinically driven 4/148 (2.7) 1/148 (0.7) 0.3707
Nonclinically driven 3/148 (2.0) 8/148 (5.4) 0.2177
TVR 6/148 (4.1) 3/148 (2.0) 0.5010
Composite endpoints, hierarchical
MACE* 9/148 (6.1) 10/148 (6.8) 0.8125
TLF* 6/148 (4.1) 3/148 (2.0) 0.5010
TVF* 15/148 (10.1) 13/148 (8.8) 0.6912
Stent thrombosis
Definite 1/158 (0.6) 1/157 (0.6) 1.0000
Acute 0/158 (0) 0/157 (0) —
Subacute 0/158 (0) 1/157 (0.6) 0.4984
Late 1/158 (0.6) 0/157 (0) 1.0000
Probable 0/158 (0) 0/157 (0) —
Acute 0/158 (0) 0/157 (0) —
Subacute 0/158 (0) 0/157 (0) —
Late 0/158 (0) 0/157 (0) —
Possible 2/158 (1.3) 0/157 (0) 0.4984
Acute 0/158 (0) 0/157 (0) —
Subacute 0/158 (0) 0/157 (0) —
Late 2/158 (1.3) 0/157 (0) 0.4984
Values are n/N (%). *MACE is the composite of cardiac death, MI, and TLR. TLF is the composite of
cardiac death, target vessel MI, and clinically indicated TLR. TVF is the composite of all death, MI,
and all repeat revascularization.
MACE  major adverse cardiac events; MI  myocardial infarction; TLF  target lesion failure;
LR  target lesion revascularization; TVF  target vessel failure; TVR  target vessel
revascularization.in any of the assessed clinical outcomes (Table 3), although
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arm (Figs. 3A and 3B). The same trend was maintained in
the diabetic subset (major adverse cardiac events: 4.5% vs.
11.1%, respectively, for Cre8 and Taxus, p  NS).
TLR were performed in 7 patients (4.7%) treated with Cre8
stents and in 9 patients (6.1%) treated with Taxus stents.
Moreover, 3 patients experienced MI: 2 in the Taxus group
(1.4%), 1 due to a spontaneous dissection in a nontarget vessel
and 1 related to definite stent thrombosis; 1 in Cre8 arm
(0.7%), related to a definite stent thrombosis. The patient
implanted with Taxus was later found to be a nonresponder to
clopidogrel, whereas the subject who received the Cre8 stent
interrupted the aspirin therapy and was later found to be a
Figure 3 Major Adverse Cardiac Events at 12-Month Follow-Up
(A) Any major adverse cardiac event. (B) Target lesion revascularization.nonresponder to thienopyridine due to genetic mutation.Three cardiac deaths occurred: 2 patients (1.4%), implanted with
Cre8, died suddenly 3 and 11 months after the index procedures.
One patient (0.7%), who received a Taxus stent, had a cardiac
arrest due to a spontaneous dissection in a nontarget vessel 2
months after the procedure. One (0.7%) vascular death, related to
fatal cerebral bleeding, and 1 (0.7%) noncardiovascular death due
to sepsis occurred in the Taxus arm.
Discussion
This is the first study to assess the role of the Cre8 stent.
This technology, based on PF abluminal reservoir elution,
may remove a major cause of late stent thrombosis, which
still remains a DES limitation (1–4), namely the vessel wall
1376 Carrié et al. JACC Vol. 59, No. 15, 2012
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drug residues on the stent luminal side, which may impair
the vessel healing. Pathological studies have suggested
inflammation caused by PP as a potential cause (7–9).
Pre-clinical studies, performed on Cre8 using a PP Cypher
stent (Cordis, Miami Lakes, Florida) as a control have shown
a reduced neointimal thickness and inflammatory score, as well
as a drug washout, into the systemic circulation, that is
significantly lower than the one for Cypher. Moreover, the
amphilimus formulation was completely eluted from the reservoirs
within 3 months, leaving an iCarbofilm-coated stent behind (15).
These distinctive Cre8 features may take a role in
reducing the need for prolonged dual-antiplatelet therapy.
In the clinical setting, the present noninferiority study
achieved its primary endpoint, demonstrating that PF Cre8
was noninferior, and even superior, to PP Taxus in terms of
6-month LLL. The IVUS analysis further supported the
superior antirestenotic efficacy of Cre8, demonstrating signif-
icantly lower neointimal hyperplasia and volume obstruction.
The relative efficacy of different DES in diabetic patients
remains controversial. Paclitaxel has been postulated to be a
particularly effective drug in diabetic patients (16), when
compared to everolimus (Xience, Abbott Vascular, Abbott
Park, Illinois) in SPIRIT (Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System)
trials (17), but sirolimus, eluted from a PP Cypher stent, has
always been detected as superior in inhibiting the restenotic
process (18,19). The present post-hoc analysis on diabetics
evidenced a statistically significant lower LLL and a trend
toward better clinical outcomes for the Cre8 stent, com-
pared with the Taxus stent, suggesting superior efficacy of
the PF amphiphilic sirolimus formulation.
Study limitations. Taxus was chosen as a comparator as
it was the most widely used DES when the study was
designed. The 6-month angiographic control may not
have captured the point of maximum LLL for either
stent. However, 12-month outcomes significantly corre-
late with later clinical outcomes. Larger studies and
longer follow-up are needed to thoroughly assess clinical
endpoints.
Conclusions
The Cre8 stent in de novo lesions showed significantly
lower in-stent LLL at 6 months than the Taxus Liberté
stent did, with a trend toward better 12-month clinical
safety and efficacy results.
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